09:56 AM EDT, 05/12/2025 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Monday it has agreed to sell its Rare Pediatric Disease Priority Review Voucher for Zevaskyn for gross proceeds of $155 million.

The company said it was awarded the priority review voucher following the US Food and Drug Administration's approval of Zevaskyn in April.

"With proceeds from this PRV sale, we have sufficient cash for more than two years of operating expenses without the need for capital infusion and not accounting for Zevaskyn sales," said Abeona Chief Financial Officer Joe Vazzano.

Vazzano said that with Zevaskyn becoming available to treat patients starting in Q3, the company expects to become profitable in early 2026.

The company's shares were rising 14.5% in recent Monday trading.

Price: 6.10, Change: +0.83, Percent Change: +15.75